封面
市場調查報告書
商品編碼
1986467

藥品安全監測和藥品安全軟體市場報告:按功能、交付方式、最終用戶和地區分類(2026-2034 年)

Pharmacovigilance and Drug Safety Software Market Report by Functionality, Delivery Mode, End User, and Region 2026-2034

出版日期: | 出版商: IMARC | 英文 135 Pages | 商品交期: 2-3個工作天內

價格

2025年,全球藥品安全監測和藥品安全軟體市場規模達2.262億美元。展望未來,IMARC Group預測,到2034年,該市場規模將達到3.617億美元,2026年至2034年的複合年成長率(CAGR)為5.19%。推動市場成長的主要因素包括:慢性病在人群中的日益普遍、藥品銷售監管的日益嚴格,以及軟體功能和使用者友善介面的不斷進步。

藥物警戒和藥物警戒軟體是指專門設計的電腦程序,旨在簡化和加強對不利事件(ADR)及其他藥物相關安全問題的監測、分析和報告。這些軟體系統在藥物警戒領域中發揮著至關重要的作用,藥物警戒致力於確保藥物的安全有效使用。這些軟體解決方案使製藥公司、監管機構和醫療保健專業人員能夠有效率地收集、管理和分析大量的藥物安全資料。它們還有助於發現潛在風險和模式,從而實現及時干預和風險緩解策略。

藥物警戒和藥物安全軟體市場的發展主要得益於臨床研究機構和外包公司對這類軟體解決方案的日益普及。這些機構認知到,健全的藥物警戒系統對於確保在開發藥物和上市後監測藥物的安全性和有效性至關重要。此外,慢性病盛行率的上升也促進了市場成長。隨著需要長期用藥的患者數量增加,對有效藥物安全監測和管理的需求也日益成長。同時,由於世界各國政府對藥物商業化實施了嚴格的監管,藥物安全法規的複雜性也隨之增加,進一步刺激了市場需求。此外,最尖端科技技術的普及也使得藥物安全檢測和藥物安全軟體的實施更加便捷。軟體功能的不斷發展和方便用戶使用介面的日益完善,也使得各機構能夠輕鬆地將這些解決方案部署並整合到現有工作流程中,從而對市場產生積極影響。

藥物安全檢測和藥物安全軟體市場的趨勢和促進因素:

製藥業的擴張

製藥業的蓬勃發展對全球藥物安全檢測(PV)和藥物安全軟體市場產生了顯著影響。隨著製藥業的擴張,新藥和新療法的研發日益增加。這推動了對藥物警戒和藥物安全軟體的需求,使其能夠監測、分析和管理不利事件,從而帶動了此類軟體需求的成長。此外,製藥業的擴張也增加了數據量和數據的複雜性,需要先進的軟體來管理和分析這些數據。這促使人工智慧和機器學習技術在藥物警戒和藥物安全軟體中開發和應用,以有效處理此類複雜的資料集。此外,藥物安全檢測和藥物安全軟體也支援風險管理需求,而日益成長的風險管理需求也推動了該市場的發展。

不利事件發生率增加

不利事件(ADR)發生率的不斷上升正對全球藥物警戒和藥物安全軟體市場產生重大影響。報告的不良藥物事件數量的增加,推動了對強大的藥物警戒系統和軟體解決方案的需求日益成長,以確保上市藥物的安全性和有效性。不利事件可能對患者的健康和福祉造成嚴重後果,甚至導致住院、額外的醫療費用,甚至死亡。因此,世界各地的監管機構正在實施嚴格的指導方針和法規,以確保製藥公司能夠有效監測和報告不良藥物事件。因此,全球藥物安全檢測和藥物安全軟體市場正經歷顯著成長,這正是對不良藥物事件發生率上升的直接回應。這是因為提供這些軟體解決方案的公司不斷創新,提供能夠有效處理大量不利事件資料的先進工具和功能。

醫療保健支出不斷增加

隨著全球醫療保健支出持續成長,最佳化病人安全和提升整體醫療服務品質的重要性日益凸顯。藥物安全檢測和藥物安全軟體在實現這些目標中發揮著至關重要的作用,它們能夠有效監測、評估和管理不利事件(ADR)及其他藥物相關問題。隨著醫療保健支出的增加,對病人安全的關注度也隨之提升。藥物安全檢測軟體為醫療機構和監管機構提供監測和預防藥物不良事件的工具,從而減輕與藥物相關不利事件相關的經濟負擔。此外,隨著醫療保健成本的不斷攀升,資源最佳化至關重要。藥物安全檢測軟體還能有效管理不利事件數據,並簡化通報和分析流程。

目錄

第1章:序言

第2章:調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 次要訊息
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 調查方法

第3章執行摘要

第4章:引言

第5章:全球藥品安全監測與藥品安全軟體市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔:依功能分類

  • 不利事件通報軟體
  • 藥品安全審核軟體
  • 問題追蹤軟體
  • 完全整合的軟體

第7章 市場區隔:依交付方式分類

  • 現場
  • 基於雲端的

第8章 市場區隔:依最終用戶分類

  • 製藥和生物技術公司
  • CRO(藥物研發合約研究組織)
  • 業務流程外包公司
  • 其他

第9章 市場區隔:依地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第10章 SWOT 分析

第11章:價值鏈分析

第12章:波特五力分析

第13章:價格分析

第14章 競爭格局

  • 市場結構
  • 主要企業
  • 主要企業簡介
    • AB Cube SAS
    • Anju Software
    • ArisGlobal
    • Ennov
    • Extedo
    • Honeywell International Inc.
    • IQVIA Inc.
    • Oracle
    • Sarjen Systems Pvt. Ltd.
    • United BioSource LLC
    • Veeva Systems Inc.
Product Code: SR112026A5030

The global pharmacovigilance and drug safety software market size reached USD 226.2 Million in 2025. Looking forward, IMARC Group expects the market to reach USD 361.7 Million by 2034, exhibiting a growth rate (CAGR) of 5.19% during 2026-2034. The growing prevalence of chronic diseases among the masses, the implementation of strict regulations on the commercialization of drugs, and continual advancements in software capabilities and user-friendly interfaces are some of the major factors propelling the market.

Pharmacovigilance and drug safety software refers to specialized computer programs designed to streamline and enhance the monitoring, analysis, and reporting of adverse drug reactions (ADRs) and other drug-related safety concerns. These software systems play a crucial role in the field of pharmacovigilance, which is dedicated to ensuring the safe and effective use of medications. These software solutions enable pharmaceutical companies, regulatory authorities, and healthcare professionals to efficiently collect, manage, and analyze large volumes of data pertaining to drug safety. They also facilitate the detection of potential risks and patterns, allowing for timely intervention and risk mitigation strategies.

The pharmacovigilance and drug safety software market is driven by the increasing adoption of these software solutions by clinical research and outsourcing companies. These organizations recognize the importance of robust pharmacovigilance systems to ensure the safety and efficacy of drugs in development and post-marketing surveillance. Moreover, the growing prevalence of chronic diseases is also contributing to the growth of the market. As the number of patients requiring long-term medication increases, so does the need for effective drug safety monitoring and management. Apart from this, governments worldwide are imposing strict regulations on the commercialization of drugs, leading to increased complexity in drug safety regulations, further impelling the demand. Besides, the availability of cutting-edge technology is facilitating the easy adoption of pharmacovigilance and drug safety software. Furthermore, continual advancements in software capabilities and user-friendly interfaces make it easier for organizations to implement and integrate these solutions into their existing workflows, thus impacting the market favorably.

PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET TRENDS/DRIVERS:

Expansion of the Pharmaceutical Industry

The development of the pharmaceutical industry is having a significant influence on the global pharmacovigilance (PV) and drug safety software market. As the pharmaceutical industry expands, there has been an increase in the development of new drugs and therapies. This leads to a greater need for PV and drug safety software to monitor, analyze, and manage adverse events, leading to an increase in demand for this software. Moreover, the pharmaceutical industry's expansion has led to a rise in data volume and complexity, requiring sophisticated software for managing and analyzing data. This is driving the development and adoption of AI and machine learning within PV and drug safety software to handle, such complex datasets effectively. Also, pharmacovigilance and drug safety software help manage these risks, and the growing need for risk management is driving demand in this market.

Growing Incidence of Adverse Drug Reactions

The increasing incidence of adverse drug reactions (ADRs) is significantly influencing the global pharmacovigilance and drug safety software market. The raising number of reported ADRs has created a greater need for robust pharmacovigilance systems and software solutions to ensure the safety and efficacy of drugs in the market. Adverse drug reactions can have serious consequences on patient health and well-being, leading to hospitalizations, additional medical costs, and even fatalities. Therefore, regulatory authorities worldwide have implemented stringent guidelines and regulations for pharmaceutical companies to monitor and report ADRs effectively. Along with this, the global pharmacovigilance and drug safety software market has experienced significant growth as a direct response to the rising incidence of ADRs since companies offering these software solutions are continuously innovating to provide advanced tools and functionalities that can handle large volumes of adverse event data efficiently.

The Increasing Healthcare Expenditure

As healthcare expenditure continues to rise globally, there is a growing emphasis on optimizing patient safety and improving the overall quality of healthcare delivery. Pharmacovigilance and drug safety software play a crucial role in achieving these objectives by ensuring the effective monitoring, assessment, and management of adverse drug reactions (ADRs) and other drug-related problems. With higher healthcare spending, there has been a growing focus on patient safety. Pharmacovigilance software provides healthcare organizations and regulatory authorities with the tools to monitor and prevent ADRs, thereby reducing the economic burden associated with medication-related harm. Moreover, healthcare expenditure growth necessitates the optimization of resources. Furthermore, pharmacovigilance software enables the efficient management of adverse event data, streamlining the reporting and analysis processes.

PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE INDUSTRY SEGMENTATION:

Breakup by Functionality:

  • Adverse Event Reporting Software
  • Drug Safety Audits Software
  • Issue Tracking Software
  • Fully Integrated Software

Adverse event reporting software dominates the market

Adverse event reporting software dominates the market as it is a critical aspect of regulatory compliance in the healthcare and pharmaceutical industries. It offers robust data management capabilities, allowing efficient collection, organization, and analysis of adverse event data. It enables the identification of patterns, trends, and potential safety issues associated with specific products or interventions. This data-driven approach helps pharmaceutical companies, healthcare providers, and regulatory agencies make informed decisions regarding product safety and risk mitigation strategies. Additionally, it provides a systematic and standardized approach to capturing and reporting these events, ensuring compliance with regulatory requirements. It provides a centralized platform for healthcare professionals, drug safety experts, and other stakeholders involved in adverse event reporting. Additionally, the software can scale to handle large volumes of adverse event data, ensuring its effectiveness even for organizations with extensive reporting requirements.

Breakup by Delivery Mode:

  • On-premises
  • Cloud-based

On- premises delivery holds the largest share in the market

On-premises deployment holds the largest share of the market as it provides organizations with a higher level of control and security over their data. It offers greater flexibility for customization and integration with existing systems. Organizations can tailor the software to their specific requirements and integrate it seamlessly with other on-premises applications or infrastructure. This level of customization and integration is beneficial for organizations with complex IT environments or unique business processes. The deployment allows organizations to maintain data sovereignty by ensuring that sensitive data remains within the borders of their own country. Moreover, the widespread adoption of on-premises software help eliminate the potential performance issues related to network latency or dependence on internet connectivity. Also, it allows organizations to maintain compliance and meet regulatory standards more easily.

Breakup by End User:

  • Pharmaceutical and Biotechnology Companies
  • Contract Research Organizations
  • Business Process Outsourcing Firms
  • Others

Contract research organizations hold the largest share in the market

CROs hold a significant position and are the leading users of the market's products or services. They specialize in providing comprehensive research services, allowing pharmaceutical and biotech companies to outsource various aspects of their R&D activities. This outsourcing model offers numerous benefits, including access to specialized expertise, reduced operational costs, and increased efficiency in trial execution. They provide in-depth knowledge of industry best practices, regulatory requirements, and emerging trends which makes it an attractive choice for companies seeking reliable partners to navigate complex research processes and achieve successful outcomes. They also have the ability to scale their resources and infrastructure according to project requirements, enabling them to support both small-scale studies and large multinational trials. They can provide expertise in risk management, data integrity, and compliance, helping companies navigate the complex regulatory landscape and mitigate potential pitfalls.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America exhibits a clear dominance, accounting for the largest pharmacovigilance and drug safety software market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others), Latin America (Brazil, Mexico, and others), and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America has a robust and well-established pharmaceutical industry, with numerous companies involved in drug discovery, development, and commercialization. The region is at the forefront of technological innovation, including advancements in healthcare and information technology. The region has a robust IT infrastructure, a favorable investment climate for research and development, and a strong focus on adopting digital solutions. North American pharmaceutical companies and research institutions often collaborate with academic institutions, healthcare providers, and technology companies to drive innovation in pharmacovigilance and drug safety. These collaborations foster the development and adoption of state-of-the-art software solutions, further enhancing North America's dominance in the market. Additionally, the region has stringent regulatory requirements for drug safety and pharmacovigilance is another significant factor responsible for impelling the market across the North America region.

COMPETITIVE LANDSCAPE:

Top companies in the market are investing in research and development activities to create advanced pharmacovigilance and drug safety software solutions. These software platforms are designed to capture, process, analyze, and report adverse events, safety data, and other relevant information related to pharmaceutical products and medical interventions. Various companies offer flexible and scalable software platforms that can be tailored to meet the unique needs of pharmaceutical companies, CROs, and healthcare institutions. Additionally, companies leverage advanced data analytics techniques, such as artificial intelligence (AI) and machine learning (ML), to analyze large volumes of safety data and identify potential safety signals. These analytics capabilities help in the early detection of adverse events, signal management, risk assessment, and trend analysis.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

  • AB Cube S.A.S.
  • Anju Software
  • ArisGlobal
  • Ennov
  • Extedo
  • Honeywell International Inc.
  • IQVIA Inc.
  • Oracle
  • Sarjen Systems Pvt. Ltd.
  • United BioSource LLC
  • Veeva Systems Inc.

KEY QUESTIONS ANSWERED IN THIS REPORT

1. What was the size of the global pharmacovigilance and drug safety software market in 2025?

2. What is the expected growth rate of the global pharmacovigilance and drug safety software market during 2026-2034?

3. What has been the impact of COVID-19 on the global pharmacovigilance and drug safety software market?

4. What are the key factors driving the global pharmacovigilance and drug safety software market?

5. What is the breakup of the global pharmacovigilance and drug safety software market based on the functionality?

6. What is the breakup of the global pharmacovigilance and drug safety software market based on the delivery mode?

7. What is the breakup of the global pharmacovigilance and drug safety software market based on the end user?

8. What are the key regions in the global pharmacovigilance and drug safety software market?

9. Who are the key players/companies in the global pharmacovigilance and drug safety software market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Pharmacovigilance and Drug Safety Software Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Functionality

  • 6.1 Adverse Event Reporting Software
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Drug Safety Audits Software
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Issue Tracking Software
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Fully Integrated Software
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Delivery Mode

  • 7.1 On-premises
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Cloud-based
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Pharmaceutical and Biotechnology Companies
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Contract Research Organizations
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Business Process Outsourcing Firms
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 AB Cube S.A.S.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
    • 14.3.2 Anju Software
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
    • 14.3.3 ArisGlobal
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
    • 14.3.4 Ennov
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
    • 14.3.5 Extedo
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
    • 14.3.6 Honeywell International Inc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
    • 14.3.7 IQVIA Inc.
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Oracle
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Sarjen Systems Pvt. Ltd.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
    • 14.3.10 United BioSource LLC
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
    • 14.3.11 Veeva Systems Inc.
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Pharmacovigilance and Drug Safety Software Market: Major Drivers and Challenges
  • Figure 2: Global: Pharmacovigilance and Drug Safety Software Market: Sales Value (in Million USD), 2020-2025
  • Figure 3: Global: Pharmacovigilance and Drug Safety Software Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 4: Global: Pharmacovigilance and Drug Safety Software Market: Breakup by Functionality (in %), 2025
  • Figure 5: Global: Pharmacovigilance and Drug Safety Software Market: Breakup by Delivery Mode (in %), 2025
  • Figure 6: Global: Pharmacovigilance and Drug Safety Software Market: Breakup by End User (in %), 2025
  • Figure 7: Global: Pharmacovigilance and Drug Safety Software Market: Breakup by Region (in %), 2025
  • Figure 8: Global: Pharmacovigilance and Drug Safety Software (Adverse Event Reporting Software) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 9: Global: Pharmacovigilance and Drug Safety Software (Adverse Event Reporting Software) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 10: Global: Pharmacovigilance and Drug Safety Software (Drug Safety Audits Software) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 11: Global: Pharmacovigilance and Drug Safety Software (Drug Safety Audits Software) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 12: Global: Pharmacovigilance and Drug Safety Software (Issue Tracking Software) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 13: Global: Pharmacovigilance and Drug Safety Software (Issue Tracking Software) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 14: Global: Pharmacovigilance and Drug Safety Software (Fully Integrated Software) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 15: Global: Pharmacovigilance and Drug Safety Software (Fully Integrated Software) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 16: Global: Pharmacovigilance and Drug Safety Software (On-premises) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 17: Global: Pharmacovigilance and Drug Safety Software (On-premises) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 18: Global: Pharmacovigilance and Drug Safety Software (Cloud-based) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 19: Global: Pharmacovigilance and Drug Safety Software (Cloud-based) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 20: Global: Pharmacovigilance and Drug Safety Software (Pharmaceutical and Biotechnology Companies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 21: Global: Pharmacovigilance and Drug Safety Software (Pharmaceutical and Biotechnology Companies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 22: Global: Pharmacovigilance and Drug Safety Software (Contract Research Organizations) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 23: Global: Pharmacovigilance and Drug Safety Software (Contract Research Organizations) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 24: Global: Pharmacovigilance and Drug Safety Software (Business Process Outsourcing Firms) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 25: Global: Pharmacovigilance and Drug Safety Software (Business Process Outsourcing Firms) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 26: Global: Pharmacovigilance and Drug Safety Software (Other End Users) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 27: Global: Pharmacovigilance and Drug Safety Software (Other End Users) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 28: North America: Pharmacovigilance and Drug Safety Software Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 29: North America: Pharmacovigilance and Drug Safety Software Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 30: United States: Pharmacovigilance and Drug Safety Software Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 31: United States: Pharmacovigilance and Drug Safety Software Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 32: Canada: Pharmacovigilance and Drug Safety Software Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 33: Canada: Pharmacovigilance and Drug Safety Software Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 34: Asia-Pacific: Pharmacovigilance and Drug Safety Software Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 35: Asia-Pacific: Pharmacovigilance and Drug Safety Software Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 36: China: Pharmacovigilance and Drug Safety Software Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 37: China: Pharmacovigilance and Drug Safety Software Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 38: Japan: Pharmacovigilance and Drug Safety Software Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 39: Japan: Pharmacovigilance and Drug Safety Software Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 40: India: Pharmacovigilance and Drug Safety Software Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 41: India: Pharmacovigilance and Drug Safety Software Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 42: South Korea: Pharmacovigilance and Drug Safety Software Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 43: South Korea: Pharmacovigilance and Drug Safety Software Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 44: Australia: Pharmacovigilance and Drug Safety Software Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 45: Australia: Pharmacovigilance and Drug Safety Software Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 46: Indonesia: Pharmacovigilance and Drug Safety Software Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 47: Indonesia: Pharmacovigilance and Drug Safety Software Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 48: Others: Pharmacovigilance and Drug Safety Software Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 49: Others: Pharmacovigilance and Drug Safety Software Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 50: Europe: Pharmacovigilance and Drug Safety Software Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 51: Europe: Pharmacovigilance and Drug Safety Software Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 52: Germany: Pharmacovigilance and Drug Safety Software Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 53: Germany: Pharmacovigilance and Drug Safety Software Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 54: France: Pharmacovigilance and Drug Safety Software Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 55: France: Pharmacovigilance and Drug Safety Software Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 56: United Kingdom: Pharmacovigilance and Drug Safety Software Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 57: United Kingdom: Pharmacovigilance and Drug Safety Software Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 58: Italy: Pharmacovigilance and Drug Safety Software Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 59: Italy: Pharmacovigilance and Drug Safety Software Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 60: Spain: Pharmacovigilance and Drug Safety Software Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 61: Spain: Pharmacovigilance and Drug Safety Software Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 62: Russia: Pharmacovigilance and Drug Safety Software Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 63: Russia: Pharmacovigilance and Drug Safety Software Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 64: Others: Pharmacovigilance and Drug Safety Software Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 65: Others: Pharmacovigilance and Drug Safety Software Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 66: Latin America: Pharmacovigilance and Drug Safety Software Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 67: Latin America: Pharmacovigilance and Drug Safety Software Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 68: Brazil: Pharmacovigilance and Drug Safety Software Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 69: Brazil: Pharmacovigilance and Drug Safety Software Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 70: Mexico: Pharmacovigilance and Drug Safety Software Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 71: Mexico: Pharmacovigilance and Drug Safety Software Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 72: Others: Pharmacovigilance and Drug Safety Software Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 73: Others: Pharmacovigilance and Drug Safety Software Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 74: Middle East and Africa: Pharmacovigilance and Drug Safety Software Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 75: Middle East and Africa: Pharmacovigilance and Drug Safety Software Market: Breakup by Country (in %), 2025
  • Figure 76: Middle East and Africa: Pharmacovigilance and Drug Safety Software Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 77: Global: Pharmacovigilance and Drug Safety Software Industry: SWOT Analysis
  • Figure 78: Global: Pharmacovigilance and Drug Safety Software Industry: Value Chain Analysis
  • Figure 79: Global: Pharmacovigilance and Drug Safety Software Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Pharmacovigilance and Drug Safety Software Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Pharmacovigilance and Drug Safety Software Market Forecast: Breakup by Functionality (in Million USD), 2026-2034
  • Table 3: Global: Pharmacovigilance and Drug Safety Software Market Forecast: Breakup by Delivery Mode (in Million USD), 2026-2034
  • Table 4: Global: Pharmacovigilance and Drug Safety Software Market Forecast: Breakup by End User (in Million USD), 2026-2034
  • Table 5: Global: Pharmacovigilance and Drug Safety Software Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 6: Global: Pharmacovigilance and Drug Safety Software Market: Competitive Structure
  • Table 7: Global: Pharmacovigilance and Drug Safety Software Market: Key Players